TYPE I GAUCHER DISEASE IN CHILDREN WITH AND WITHOUT ENZYME THERAPY

By Dweck Altoon   Abrahamov Ayala   Hadas-Halpern Irith   Bdolach-Avram Tali   Zimran Ari   Elstein Deborah  

Pediatric Hematology and Oncology, Vol. 19, Iss. 6, 2002-09 ,pp. : 389-397

Informa Healthcare

Access to resources Recommend Favorite

Postmortem studies on a patient with mucopolysaccharidosis type I: Histopathological findings after one year of enzyme replacement therapy

By Yano S.   Moseley K.   Pavlova Z.  

Journal of Inherited Metabolic Disease, Vol. 32, Iss. 1, 2009-12 ,pp. : 53-57

Springer Publishing Company

Access to resources Recommend Favorite

Gaucher disease and bone: Laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy

By Ciana G.   Addobbati R.   Tamaro G.   Leopaldi A.   Nevyjel M.   Ronfani L.   Vidoni L.   Pittis M.   Bembi B.  

Journal of Inherited Metabolic Disease, Vol. 28, Iss. 5, 2005-09 ,pp. : 723-732

Springer Publishing Company

Access to resources Recommend Favorite

Neurological outcome of a patient with Gaucher disease type III treated by enzymatic replacement therapy

By Dobbelaere D.   Sukno S.   defoort-Dhellemmes S.     Largillière C.  

Journal of Inherited Metabolic Disease, Vol. 21, Iss. 1, 1998-01 ,pp. : 74-76

Springer Publishing Company

Access to resources Recommend Favorite

Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy

By Marshall John   McEachern Kerry   Chuang Wei-Lien   Hutto Elizabeth   Siegel Craig   Shayman James   Grabowski Greg   Scheule Ronald   Copeland Diane   Cheng Seng  

Journal of Inherited Metabolic Disease, Vol. 33, Iss. 3, 2010-06 ,pp. : 281-289

Springer Publishing Company

Access to resources Recommend Favorite